|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||87.08 - 87.37|
|52-week range||87.08 - 87.37|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||19.10|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).
Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.